Loading...
OTCM
RGIN
Market cap15kUSD
Jul 28, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-99.91%
IPO
-99.85%
Name

Regenicin Inc

Chart & Performance

D1W1MN
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
%
Revenues
0k
Net income
-694k
L-23.88%
-4,000-44,500-11,000-935,250-3,665,582000242,599-1,089,902-973,937-559,058-776,409-606,641-911,815-694,041
CFO
-27k
L+13.21%
-8,000-35,000-15,500-346,617-1,774,552-1,058,929-685,142-211,845-1,996,685-693,272-311,705-133,721-126,862-123,199-24,107-27,291

Profile

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
IPO date
May 12, 2008
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
Cost of revenue
1,202
Unusual Expense (Income)
NOPBT
(1,202)
NOPBT Margin
Operating Taxes
55
Tax Rate
NOPAT
(1,257)
Net income
(694)
-23.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
643
Long-term debt
Deferred revenue
Other long-term liabilities
1
Net debt
627
Cash flow
Cash from operating activities
(27)
CAPEX
Cash from investing activities
Cash from financing activities
40
FCF
(863)
Balance
Cash
15
Long term investments
Excess cash
15
Stockholders' equity
(15,801)
Invested Capital
10,847
ROIC
ROCE
24.27%
EV
Common stock shares outstanding
153,483
Price
Market cap
EV
EBITDA
(1,202)
EV/EBITDA
Interest
36
Interest/NOPBT